Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture

20071,985 citationsJournal Articlebronze Open Access

Authors

Kenneth W. Lyles · Duke Medical Center

Cathleen Colón‐Emeric · Duke Medical Center

Jay Magaziner · University of Maryland, Baltimore

Jonathan D. Adachi · McMaster University

Carl F. Pieper · Duke Medical Center

C. Mautalén

Lars Hyldstrup · Hvidovre Hospital

Abstract

An annual infusion of zoledronic acid within 90 days after repair of a low-trauma hip fracture was associated with a reduction in the rate of new clinical fractures and with improved survival. (ClinicalTrials.gov number, NCT00046254 [ClinicalTrials.gov].).

Topics & Keywords

Bone and Joint Diseases Hip and Femur Fractures Bone health and treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 357, Issue 18, pp. 1799-1809

DOI: 10.1056/nejmoa074941

Field-Weighted Citation Impact: 114.66